• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血糖控制不佳的糖尿病对红细胞寿命影响的研究

Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life.

作者信息

Sayinalp S, Sözen T, Usman A, Dündar S

机构信息

Department of Internal Medicine, Hacettepe University, School of Medicine, Ankara, Turkey.

出版信息

J Diabetes Complications. 1995 Jul-Sep;9(3):190-3. doi: 10.1016/1056-8727(94)00041-l.

DOI:10.1016/1056-8727(94)00041-l
PMID:7548984
Abstract

Erythrocyte half-life (Et-1/2) has been measured in 11 patients with poorly controlled blood sugar levels and compared with a normal control group to determine whether decreased red cell deformability, which occurs in diabetic patients, causes shortening of erythrocyte life or not. No difference was seen (Et-1/2 = 28.1 days in diabetic patients and 28.5 days in controls). There was also no correlation between Et-1/2 and glycosylated hemoglobin (HbA1) levels. It has been concluded that poorly controlled diabetes mellitus has no effect upon erythrocyte life.

摘要

已对11名血糖控制不佳的患者测量了红细胞半衰期(Et-1/2),并与正常对照组进行比较,以确定糖尿病患者出现的红细胞变形性降低是否会导致红细胞寿命缩短。未发现差异(糖尿病患者的Et-1/2为28.1天,对照组为28.5天)。Et-1/2与糖化血红蛋白(HbA1)水平之间也没有相关性。得出的结论是,血糖控制不佳的糖尿病对红细胞寿命没有影响。

相似文献

1
Investigation of the effect of poorly controlled diabetes mellitus on erythrocyte life.血糖控制不佳的糖尿病对红细胞寿命影响的研究
J Diabetes Complications. 1995 Jul-Sep;9(3):190-3. doi: 10.1016/1056-8727(94)00041-l.
2
No decreased erythrocyte deformability in type 1 (insulin-dependent) diabetes, either by filtration or by ektacytometry.无论是通过过滤法还是激光衍射法检测,1型(胰岛素依赖型)糖尿病患者均未出现红细胞变形性降低的情况。
Acta Diabetol. 1993;30(2):89-92. doi: 10.1007/BF00578220.
3
Assessment of erythrocyte morphology in patients with type 2 diabetes mellitus: a pilot study of electron microscopy-based analysis in relation to healthy controls.红细胞形态学评估在 2 型糖尿病患者中的应用:一项基于电子显微镜分析的初步研究,涉及与健康对照组的比较。
Turk J Med Sci. 2021 Oct 21;51(5):2534-2542. doi: 10.3906/sag-2103-336.
4
Progressive impairment of erythrocyte deformability as indicator of microangiopathy in type 2 diabetes mellitus.红细胞变形能力进行性损害作为2型糖尿病微血管病变的指标
Clin Hemorheol Microcirc. 2007;36(3):253-61.
5
Glycosylated haemoglobin and blood glucose levels in Libyan diabetic patients.利比亚糖尿病患者的糖化血红蛋白和血糖水平
Trop Geogr Med. 1986 Dec;38(4):391-7.
6
Evaluation of red cell deformability by a filtration method in type 1 and type 2 diabetes mellitus with and without vascular complications.采用过滤法对伴有和不伴有血管并发症的1型和2型糖尿病患者的红细胞变形性进行评估。
Diabetes Res. 1990 Feb;13(2):61-5.
7
Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients.红细胞脆性随 2 型糖尿病患者糖化血红蛋白水平的升高而增加。
Clin Hemorheol Microcirc. 2009;43(4):345-51. doi: 10.3233/CH-2009-1245.
8
[Behavior of glycosylated hemoglobin (HbA1) and fasting blood glucose in normal subjects and in patients with diabetes mellitus].[正常人和糖尿病患者糖化血红蛋白(HbA1)及空腹血糖的变化]
AMB Rev Assoc Med Bras. 1985 Nov-Dec;31(11-12):227-31.
9
No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.I型和II型糖尿病患者的血糖控制与红细胞醛糖还原酶活性增加之间无相关性。
J Diabetes Complications. 1992 Apr-Jun;6(2):111-5. doi: 10.1016/1056-8727(92)90021-c.
10
Effects of diabetic control and biosynthetic human insulin on blood rheology in established diabetics.糖尿病控制及生物合成人胰岛素对已确诊糖尿病患者血液流变学的影响。
Diabetes Res. 1984 May;1(1):27-30.

引用本文的文献

1
Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.糖尿病中的贫血:发病机制及早期促红细胞生成素治疗的价值。
Metabol Open. 2025 Jan 4;25:100344. doi: 10.1016/j.metop.2024.100344. eCollection 2025 Mar.
2
Do We Store Packed Red Blood Cells under "Quasi-Diabetic" Conditions?我们是否在“类糖尿病”条件下储存浓缩红细胞?
Biomolecules. 2021 Jul 5;11(7):992. doi: 10.3390/biom11070992.
3
In utero nanoparticle delivery for site-specific genome editing.子宫内纳米颗粒传递用于特定部位的基因组编辑。
Nat Commun. 2018 Jun 26;9(1):2481. doi: 10.1038/s41467-018-04894-2.
4
Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine: An American Perspective.可能会改变糖化血红蛋白(HbA1C)在临床医学中解释及意义的生理学概念:美国视角
J Diabetes Sci Technol. 2015 May;9(3):696-700. doi: 10.1177/1932296815572255. Epub 2015 Feb 17.
5
Validation of a hemoglobin A1c model in patients with type 1 and type 2 diabetes and its use to go beyond the averaged relationship of hemoglobin A1c and mean glucose level.1型和2型糖尿病患者血红蛋白A1c模型的验证及其用于超越血红蛋白A1c与平均血糖水平的平均关系。
J Transl Med. 2014 Dec 10;12:328. doi: 10.1186/s12967-014-0328-5.
6
Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c.血液学正常人群中红细胞寿命的异质性足以改变糖化血红蛋白(HbA1c)。
Blood. 2008 Nov 15;112(10):4284-91. doi: 10.1182/blood-2008-04-154112. Epub 2008 Aug 11.
7
Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes.临床1型糖尿病中因糖基化、氧化和硝化作用而受损的蛋白质的降解产物
Diabetologia. 2005 Aug;48(8):1590-603. doi: 10.1007/s00125-005-1810-7. Epub 2005 Jun 30.